Compare CBU & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | ABCL |
|---|---|---|
| Founded | 1866 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 1994 | 2020 |
| Metric | CBU | ABCL |
|---|---|---|
| Price | $58.55 | $12.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $69.17 | $16.70 |
| AVG Volume (30 Days) | 261.6K | ★ 5.0M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | ★ 15.41 | 10.91 |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $818,007,000.00 | $75,128,000.00 |
| Revenue This Year | $9.59 | N/A |
| Revenue Next Year | $7.68 | $7.91 |
| P/E Ratio | $26.38 | ★ N/A |
| Revenue Growth | 9.61 | ★ 160.56 |
| 52 Week Low | $53.46 | $2.75 |
| 52 Week High | $71.11 | $14.98 |
| Indicator | CBU | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 27.82 | 50.89 |
| Support Level | $56.74 | $11.78 |
| Resistance Level | $58.83 | $12.88 |
| Average True Range (ATR) | 1.05 | 0.83 |
| MACD | -0.13 | -0.22 |
| Stochastic Oscillator | 5.23 | 21.09 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional, and governmental customers. The Company also offers comprehensive financial planning, trust administration, and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services, and Wealth Management Services. The group generates the majority of its revenue from the Banking and Corporate segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.